Dose reduction of ibrutinib in chronic lymphocytic leukemia: long-term outcomes from a real-world single-center experience. Mediterr J Hematol Infect Dis [Internet]. 2026 Oct. 31 [cited 2026 Nov. 1];18(1):e2026090. Available from: https://www.mjhid.org/mjhid/article/view/6535